Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,327,656
  • Shares Outstanding, K 210,739
  • Annual Sales, $ 450,710 K
  • Annual Income, $ -88,880 K
  • EBIT $ 76 M
  • EBITDA $ 66 M
  • 60-Month Beta 0.83
  • Price/Sales 2.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 77.34% (-81.84%)
  • Historical Volatility 45.61%
  • IV Percentile 88%
  • IV Rank 32.87%
  • IV High 167.17% on 02/04/26
  • IV Low 33.36% on 08/26/25
  • Expected Move (DTE 9) 0.79 (12.07%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 398
  • Volume Avg (30-Day) 2,487
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 42,577
  • Open Int (30-Day) 44,720
  • Expected Range 5.76 to 7.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.06
  • Number of Estimates 4
  • High Estimate 0.12
  • Low Estimate 0.02
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +146.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.23 +5.14%
on 02/05/26
7.33 -10.64%
on 01/12/26
-0.85 (-11.49%)
since 01/09/26
3-Month
6.23 +5.14%
on 02/05/26
8.17 -19.83%
on 12/04/25
-0.65 (-9.03%)
since 11/10/25
52-Week
6.00 +9.17%
on 10/14/25
11.31 -42.09%
on 06/04/25
-2.08 (-24.10%)
since 02/10/25

Most Recent Stories

More News
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results...

BCRX : 6.55 (+3.97%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 6.55 (+3.97%)
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially...

BCRX : 6.55 (+3.97%)
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected...

BCRX : 6.55 (+3.97%)
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...

ATXS : 12.58 (+0.64%)
BCRX : 6.55 (+3.97%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 6.55 (+3.97%)
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44 th Annual J.P. Morgan Healthcare...

BCRX : 6.55 (+3.97%)
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- ...

BCRX : 6.55 (+3.97%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 6.55 (+3.97%)
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.  (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the...

BCRX : 6.55 (+3.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 7.03
2nd Resistance Point 6.83
1st Resistance Point 6.69
Last Price 6.55
1st Support Level 6.35
2nd Support Level 6.16
3rd Support Level 6.02

See More

52-Week High 11.31
Fibonacci 61.8% 9.28
Fibonacci 50% 8.66
Fibonacci 38.2% 8.03
Last Price 6.55
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar